Send us all your questions or requests, and our expert team will assist you.
The treatment for AL amyloidosis targets the root cause: the abnormal plasma cells in the bone marrow. The strategy mirrors the treatment for multiple myeloma. The goal is a rapid, deep hematologic response, meaning the levels of toxic light chains in the blood drop to normal levels. This stops further deposition in the kidneys.
Chemotherapy combinations are the standard of care. Regimens typically include a proteasome inhibitor (such as bortezomib), an alkylating agent (such as cyclophosphamide), and a steroid (such as dexamethasone). This “CyBorD” regimen is highly effective at rapidly killing plasma cell clones.
Recently, immunotherapy has revolutionized care. Monoclonal antibodies (like daratumumab) that target specific markers on plasma cells are now often added to frontline therapy. These drugs flag the abnormal cells for destruction by the immune system, leading to deeper and more durable responses with manageable side effects.
For eligible patients, high-dose chemotherapy followed by an autologous stem cell transplant remains a potent treatment option. This involves harvesting the patient’s own healthy stem cells, administering a high-dose chemotherapy (melphalan) to wipe out the bone marrow, and then returning the stem cells to reboot the immune system.
However, ASCT is physically demanding. Patients with advanced kidney or heart involvement may not be strong enough to survive the procedure. Careful selection is vital. Those who can undergo ASCT often achieve long-term remission, giving the kidneys the longest possible window to heal.
In AA amyloidosis, the kidney is an innocent bystander to systemic inflammation. Treatment focuses entirely on the underlying condition. If the cause is rheumatoid arthritis or Crohn’s disease, aggressive use of biologic agents (such as TNF inhibitors or IL-6 inhibitors) is employed to extinguish inflammation.
If the cause is a chronic infection like osteomyelitis or tuberculosis, surgical removal of the infected bone or long-term antibiotic therapy is required. For Familial Mediterranean Fever, the drug colchicine is highly effective at preventing attacks and stopping amyloid production.
Monitoring SAA levels in the blood is the guide for treatment. If SAA levels return to normal, the kidneys can stabilize, and existing amyloid deposits may slowly regress over time.
Treatment for hereditary forms depends on the specific mutation. For Fibrinogen amyloidosis, kidney transplantation is often necessary. However, because the liver produces the abnormal fibrinogen, the new kidney will eventually be destroyed too. Therefore, a combined liver and kidney transplant is often the curative strategy.
For other forms, emerging RNA interference therapies are being developed to stop the liver from producing the abnormal proteins. These “gene silencers” represent the future of treatment, potentially avoiding the need for liver transplantation.
While treating the underlying cause, the kidneys must be supported. This involves meticulous management of fluid balance. Diuretics (water pills) are essential to control the massive edema caused by nephrotic syndrome. Loop diuretics are often combined with other types to overcome resistance.
Blood pressure control is paramount. ACE inhibitors or ARBs are used to reduce glomerular pressure and lower protein excretion. However, these must be used cautiously if kidney function is very low or if the patient has low blood pressure due to autonomic dysfunction.
Dietary modifications, including salt restriction and controlled protein intake, help reduce the workload on the kidneys. Compression stockings are used to manage leg swelling physically. Preventing complications, such as blood clots, is also part of supportive care.
If kidney function continues to decline despite treatment, preparation for renal replacement is necessary. Dialysis (hemodialysis or peritoneal dialysis) supports the patient when the kidneys fail. Interestingly, patients with amyloidosis often tolerate dialysis poorly due to low blood pressure and heart issues.
Kidney transplantation is a viable option for patients with ESRD due to amyloidosis. In AL amyloidosis, the hematologic disease must be in deep remission before a transplant can be considered to prevent the new kidney from being immediately affected. Outcomes for amyloid patients undergoing transplant have improved significantly.
Follow-up is lifelong. In AL amyloidosis, blood tests for free light chains and cardiac biomarkers are done every 1 to 3 months. A drop in light chains usually precedes the improvement in kidney function by several months.
A decrease in proteinuria and stabilization of eGFR define renal response. It takes time for the kidneys to heal; a reduction in protein leakage may take 6 to 12 months after the blood tests normalize. Relapse of the underlying plasma cell disorder requires reinitiation of chemotherapy.
Send us all your questions or requests, and our expert team will assist you.
Not necessarily. The drugs used for AL amyloidosis (bortezomib, daratumumab) are different from the harsh chemotherapy used for solid tumors. They typically do not cause hair loss, though they can cause fatigue, neuropathy, or digestive issues. Melphalan, used in stem cell transplants, does cause hair loss.
For AL amyloidosis, initial treatment usually lasts 6 to 12 months. If a deep remission is achieved, treatment may be stopped, and the patient monitored. Some maintenance therapy may be required. For AA amyloidosis, treatment of the underlying inflammation is usually lifelong.
Yes, if the treatment is successful and the protein leakage stops, the albumin levels in the blood will rise, and the fluid will return to the vessels. The swelling can resolve completely, though this process is slow and can take many months.
It carries higher risks than a standard transplant because amyloidosis often affects other organs, like the heart. However, if the heart is stable and the underlying disease is controlled, a kidney transplant is a highly successful and life-extending option.
A hematologic response indicates that the treatment has successfully killed the cells that produce amyloid. On blood tests, this shows up as normalization of free light chain levels. This must happen before the kidney can start to heal.
Your Comparison List (you must select at least 2 packages)
